Analyst will focus on phase III studies and travel vaccines in Bavarian report
On Monday, Bavarian Nordic will release its first quarterly report for the year, and a Sydbank analyst is waiting in suspense to hear more about two phase III vaccine studies and how well travel vaccines performed.
by marketwire, translated by daniel pedersen
In the year 2022, Bavarian Nordic will be conducting two phase III studies – and investors are keeping a keen eye on news about either, when the biotech firm publicizes figures from its first financial quarterly on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
